Susquehanna International Group’s Cytek Biosciences CTKB Stock Holding History

Susquehanna International Group’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,200	Closed	-$88.6K	–	12181
2024 Q1	$88.6K	Buy	+13,200	New	+$104K	﹤0.01%	11284
2023 Q4	–	Sell	-26,000	Closed	-$144K	–	12477
2023 Q3	$144K	Sell	26,000 -15,100	-37%	-$121K	﹤0.01%	10593
2023 Q2	$351K	Buy	+41,100	New	+$369K	﹤0.01%	9122
2023 Q1	–	Sell	-56,400	Closed	-$576K	–	12674
2022 Q4	$576K	Buy	+56,400	New	+$758K	﹤0.01%	7486

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's CTKB Position: Q1 2026 in Review

Susquehanna International Group increased its Cytek Biosciences (CTKB) stake by 16% in Q1 2026, buying an estimated $37.3K and bringing the position to 56,010 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #11306.

Susquehanna International Group first reported a position in CTKB in Q1 2022 and has held it in 14 quarters since. The position peaked at $2.82M in Q1 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Susquehanna International Group held 56,010 shares of Cytek Biosciences worth $245K as of Q1 2026.
Susquehanna International Group bought 7,907 Cytek Biosciences shares in Q1 2026, an estimated $37.3K.
Cytek Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11306 holding.
Susquehanna International Group first reported a position in Cytek Biosciences in Q1 2022 and has held it in 14 quarters since.
Susquehanna International Group's Cytek Biosciences position peaked at $2.82M in Q1 2023.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.